| Literature DB >> 33958668 |
Yachana Kataria1,2, Manisha Cole3, Elizabeth Duffy3, Kyle de la Cena3, Elissa M Schechter-Perkins4, Tara C Bouton5, Martha M Werler6, Cassandra Pierre5, Elizabeth J Ragan5, Sarah E Weber5, Karen R Jacobson5, Chris Andry7,3.
Abstract
Healthcare workers (HCWs) are at an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel virus that causes Coronavirus Disease (COVID-19). We aim to assess the seroprevalence of SARS-CoV-2 IgG among healthcare workers and compare risk-factors between seropositive and seronegative HCWs. In this observational study, serum samples were collected from HCWs between July 13th to 26th, 2020 at Boston Medical Center (BMC). Samples were subsequently tested for SARS-CoV-2 IgG antibody using the Abbott SARS-CoV-2 IgG assay. Participants also answered a questionnaire capturing data on demographics, history of COVID-19 symptoms, occupation, infection prevention and control measures. Overall, 95 of 1743 (5.5%) participants tested positive for SARS-CoV-2 IgG. Of these, 1.8% of the participants had mild or no COVID-19 symptoms and did not require a diagnostic test. Seropositivity was not associated with gender, occupation, hand hygiene and personal protective equipment (PPE) practices amongst HCWs. However, lack of physical distancing among health care workers in work areas and break room was associated with seropositivity (p = 0.05, p = 0.003, respectively). The majority of the HCWs are negative for SARS-CoV-2 IgG. This data highlights the need to promote infection prevention measures, and the importance of distance amongst co-workers to help mitigate infection rates.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33958668 PMCID: PMC8102593 DOI: 10.1038/s41598-021-89107-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study enrollment.
Study demographics.
| Variable | Total | SARS-CoV-2 IgG Status | p-value† | RR (95% CI) | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Total | 1743 | 95 (5.5%) | 1648 (94.5%) | ||
| 0.55† | |||||
| Female | 1304 (74.8%) | 75 (5.8%) | 1229 (94.2%) | 1 (referent) | |
| Male | 432 (24.8%) | 20 (4.6%) | 412 (95.4%) | 0.79 (0.49–1.29) | |
| Nonbinary/third gender | 3 (0.2%) | 0 | 3 (100%) | 0 (0.00–NaN**) | |
| p < 0.001†* | |||||
| < 20 | 93 (5.3%) | 16 (17.2%) | 77 (82.8%) | 1 (referent) | |
| 20–29 | 334 (19.2%) | 17 (5.1%) | 317 (94.9%) | 0.28 (0.15–0.54)* | |
| 30–39 | 534 (30.6%) | 22 (4.1%) | 512 (95.9%) | 0.23 (0.12–0.42)* | |
| 40–49 | 322 (18.5%) | 15 (4.7%) | 307 (95.3%) | 0.26 (0.13–0.50)* | |
| 50–59 | 294 (16.9%) | 20 (6.8%) | 274 (93.2%) | 0.38 (0.20–0.70)* | |
| 60–69 | 155 (8.9%) | 5 (3.2%) | 150 (96.8%) | 0.18 (0.07–0.47)* | |
| > 69 | 11 (0.6%) | 0 | 11 (100%) | 0.00 (0.00–NaN**) | |
| 0.02†* | |||||
| Underweight | 30 (1.7%) | 0 | 30 (100%) | 0.00 (0.02–5.56) | |
| Normal | 843 (48.4%) | 39 (4.6%) | 804 (95.4%) | 1 (referent) | |
| Overweight | 529 (30.3%) | 25 (4.7%) | 504 (95.3%) | 1.00 (0.62–1.71) | |
| Obese | 335 (19.2%) | 30 (9.0%) | 305 (91.0%) | 1.97 (1.25–3.32)* | |
| 0.05† | |||||
| Yes | 143 (8.2%) | 13 (9.1%) | 130 (90.9%) | 1.79 (1.02–3.14)* | |
| No | 1594 (91.5%) | 80 (5.0%) | 1514 (95.0%) | 1 (referent) | |
| 0.54† | |||||
| Asian | 160 (9.2%) | 10 (6.3%) | 150 (93.8%) | 1.27 (0.66–2.42) | |
| Black | 142 (8.1%) | 11 (7.7%) | 131 (92.3%) | 1.57 (0.85–2.92) | |
| White | 1299 (74.5%) | 63 (4.8%) | 1236 (95.2%) | 1 (referent) | |
| Native American/Pacific Islander | 7 (0.4%) | 0 | 7 (100%) | 0.00 (0.00–NaN**) | |
| Other | 112 (6.4%) | 5 (4.5%) | 107 (95.5%) | 0.91 (0.37–2.20) | |
| 0.33† | |||||
| Yes | 47 (2.7%) | 4 (8.5%) | 43 (91.5%) | 1.55 (0.59–4.04) | |
| No | 1675 (96.1%) | 91 (5.4%) | 1584 (94.6%) | 1 (referent) | |
| 0.0028†* | |||||
| Administrative | 145 (8.3%) | 7 (4.8%) | 138 (95.2%) | 1 (referent) | |
| Allied health—non-patient facing | 112 (6.4%) | 1 (0.9%) | 111 (99.1%) | 0.16 (0.02–1.31) | |
| Allied health—patient facing | 222 (12.7%) | 19 (8.6%) | 203 (91.4%) | 1.56 (0.67–3.62) | |
| Facilities management/support services | 25 (1.4%) | 0 | 25 (100%) | 0.00 (0.00–NaN**) | |
| Medical doctor/doctor of osteopathy | 523 (30.0%) | 18 (3.4%) | 505 (96.6%) | 0.63 (0.27–1.47) | |
| Nursing | 716 (41.1%) | 50 (7.0%) | 666 (93.0%) | 1.27 (0.59–2.75) | |
†Fisher’s Exact Test, otherwise, Chi Squared.
*Statistically significant when p-value < 0.05.
**NaN is Not a Number, unable to divide by 0.
Column percentages may not always add up to 100% due to missing data. Missing data ranged from 0.11–1.32%.
Administrative: Director, Supervisor, Manager, Chairs, Admission personnel.
Allied Health: Nonpatient facing: Lab personnel, Lab Technologist, Radiology.
Allied Health: Patient facing: Technologist, Medical Assistant, Speech Pathologist, Team Leader, Occupational Therapist, Dentist, Phlebotomy, Patient Education, Pharmacy, Other.
Facilities Management: Electrician, Environmental Services, Housekeeping, Support Staff.
Medical Doctor/ Doctor of Osteopathy: Attending, Resident.
Nursing: Registered Nurse, Advanced Practice Registered Nurse, Nurse Technicians.
SARS-CoV-2 RT-PCR result by SARS-CoV-2 IgG status.
| Total | SARS-CoV-2 IgG Status | ||
|---|---|---|---|
| Positive | Negative | ||
| Total | 1743 | 95 (5.5%) | 1648 (94.5%) |
| 441 | 72 (16.3%) | 369 (83.7%) | |
| Indeterminate/no result | 6 | 1 (16.7%) | 5 (83.3%) |
| Negative | 350 | 7 (2.0%) | 343 (98.0%) |
| Positive | 85 | 64 (75.3%) | 21 (24.7%) |
| 1302 | 23 (1.8%) | 1279 (98.2%) | |
Self-Reported symptoms by SARS-CoV-2 IgG status.
| Symptoms | Total | SARS-CoV-2 IgG Status | p-value | |
|---|---|---|---|---|
| Positive | Negative | |||
| Total | 1743 | 95 (5.5%) | 1648 (94.5%) | |
| Fever** | 252 (14.5%) | 43 (17.1%) | 209 (82.9%) | p < 0.001†* |
| Sore throat*** | 608 (34.9%) | 33 (5.4%) | 575 (94.6%) | p < 0.001* |
| Cough | 611 (35.1%) | 45 (7.4%) | 566 (92.6%) | 0.02* |
| Runny nose | 672 (38.6%) | 32 (4.8%) | 640 (95.2%) | 0.39 |
| Shortness of breath | 280 (16.1%) | 30 (10.7%) | 250 (89.3%) | p < 0.001* |
| Chills | 362 (20.8%) | 43 (11.9%) | 319 (88.1%) | p < 0.001†* |
| Nausea/vomiting | 318 (18.2%) | 16 (5.0%) | 302 (95.0%) | 0.83 |
| Diarrhea | 409 (23.5%) | 26 (6.4%) | 383 (93.6%) | 0.43 |
| Headache | 869 (49.9%) | 49 (5.6%) | 820 (94.4%) | 0.81 |
| Rash | 73 (4.2%) | 3 (4.1%) | 70 (95.9%) | 0.79† |
| Muscle/joint pain | 566 (32.5%) | 56 (9.9%) | 510 (90.1%) | p < 0.001* |
| Loss of appetite | 285 (16.4%) | 36 (12.6%) | 249 (87.4%) | p < 0.001* |
| Loss of Smell/Taste | 116 (6.7%) | 44 (37.9%) | 72 (62.1%) | p < 0.001* |
| Fatigue | 815 (46.8%) | 64 (7.9%) | 751 (92.1%) | p < 0.001* |
| Seizures | 5 (0.3%) | 0 | 5 (100%) | 1.00† |
| Altered consciousness | 9 (0.5%) | 2 (22.2%) | 7 (77.8%) | 0.08† |
| Other neurological signs | 21 (1.2%) | 5 (23.8%) | 16 (76.2%) | 0.0045†* |
†Fisher’s Exact Test, otherwise, Chi Squared.
*Statistically significant when p-value < 0.05.
**Missing data included in analysis due to accounting for 5.2% of responses.
***Missing data included in analysis due to accounting for 5.3% of responses.
Column percentages may not always add up to 100% due to missing data. Missing data ranged from 0–1.03%.
Infection prevention and control measures by SARS-CoV-2 IgG status.
| Total | SARS-CoV-2 IgG Status | p-value (all data) | ||
|---|---|---|---|---|
| Positive | Negative | |||
| Total | 1743 | 95 (5.5%) | 1648 (94.5%) | |
| 0.38† | ||||
| Always | 1598 (91.7%) | 85 (5.3%) | 1513 (94.7%) | |
| Most of the time | 123 (7.1%) | 9 (7.3%) | 114 (92.7%) | |
| Occasionally | 0 | 0 | 0 | |
| Rarely | 2 (0.1%) | 0 | 2 (100%) | |
| 0.25† | ||||
| Always | 1670 (95.8%) | 89 (5.3%) | 1581 (94.7%) | |
| Most of the time | 24 (1.4%) | 3 (12.5%) | 21 (87.5%) | |
| Occasionally | 0 | 0 | 0 | |
| Rarely | 7 (0.4%) | 0 | 7 (100%) | |
| 0.50† | ||||
| Always | 1466 (84.1%) | 85 (5.8%) | 1381 (94.2%) | |
| Most of the time | 233 (13.4%) | 8 (3.4%) | 225 (96.6%) | |
| Occasionally | 5 (0.3%) | 0 | 5 (100%) | |
| Rarely | 4 (0.2%) | 0 | 4 (100%) | |
| 0.95† | ||||
| Always | 1549 (88.9%) | 85 (5.5%) | 1464 (94.5%) | |
| Most of the time | 141 (8.1%) | 8 (5.7%) | 133 (94.3%) | |
| Occasionally | 7 (0.4%) | 0 | 7 (100%) | |
| Rarely | 12 (0.7%) | 0 | 12 (100%) | |
| 0.05 | ||||
| Always | 334 (19.2%) | 13 (3.9%) | 321 (96.1%) | |
| Most of the time | 721 (41.4%) | 33 (4.6%) | 688 (95.4%) | |
| Occasionally | 320 (18.4%) | 21 (6.6%) | 299 (93.4%) | |
| Rarely | 351 (20.1%) | 28 (8.0%) | 323 (92.0%) | |
| 0.003* | ||||
| Always | 447 (25.6%) | 14 (3.1%) | 433 (96.9%) | |
| Most of the time | 689 (39.5%) | 37 (5.4%) | 652 (94.6%) | |
| Occasionally | 316 (18.1%) | 15 (4.7%) | 301 (95.3%) | |
| Rarely | 222 (12.7%) | 22 (9.9%) | 200 (90.1%) | |
†Fisher’s Exact Test, otherwise, Chi Squared.
*Statistically significant when p-value < 0.05.
Column percentages may not always add up to 100% due to missing data. Missing data ranged from 0.17–2.93%.